Cubist Systematic Strategies, LLC Sarepta Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$113.33 - $163.85 $6.18 Million - $8.93 Million	54,500 Added 58.22%	148,114 $23.4 Million
Q1 2024 May 15, 2024	BUY	$93.7 - $141.53 $4.55 Million - $6.87 Million	48,552 Added 107.74%	93,614 $12.1 Million
Q4 2023 Feb 14, 2024	BUY	$67.31 - $124.76 $1.79 Million - $3.32 Million	26,643 Added 144.65%	45,062 $4.35 Million
Q3 2023 Nov 14, 2023	SELL	$102.5 - $123.59 $6.65 Million - $8.02 Million	-64,910 Reduced 77.9%	18,419 $2.23 Million
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $1.59 Million - $2.34 Million	-14,897 Reduced 15.17%	83,329 $9.54 Million
Q1 2023 May 15, 2023	SELL	$117.53 - $155.99 $4.84 Million - $6.42 Million	-41,141 Reduced 29.52%	98,226 $13.5 Million
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $6.31 Million - $8.26 Million	-62,530 Reduced 30.97%	139,367 $18.1 Million
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $7.57 Million - $11.9 Million	99,935 Added 98.01%	201,897 $22.3 Million
Q2 2022 Aug 15, 2022	BUY	$62.69 - $88.44 $2.46 Million - $3.47 Million	39,209 Added 62.48%	101,962 $7.64 Million
Q1 2022 May 16, 2022	SELL	$63.15 - $90.42 $2.46 Million - $3.52 Million	-38,900 Reduced 38.27%	62,753 $4.9 Million
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $2.62 Million - $3.37 Million	33,928 Added 50.1%	101,653 $9.15 Million
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $703,570 - $986,299	10,665 Added 18.69%	67,725 $6.26 Million
Q2 2021 Aug 16, 2021	SELL	$69.38 - $86.75 $2.74 Million - $3.42 Million	-39,442 Reduced 40.87%	57,060 $4.44 Million
Q1 2021 May 17, 2021	BUY	$72.25 - $168.95 $6.64 Million - $15.5 Million	91,903 Added 1998.33%	96,502 $7.19 Million
Q4 2020 Feb 16, 2021	SELL	$125.56 - $178.74 $3.54 Million - $5.04 Million	-28,194 Reduced 85.98%	4,599 $784,000
Q3 2020 Nov 16, 2020	BUY	$127.12 - $172.34 $3.41 Million - $4.62 Million	26,807 Added 447.83%	32,793 $4.61 Million
Q2 2020 Aug 14, 2020	BUY	$93.0 - $171.7 $556,698 - $1.03 Million	5,986 New	5,986 $960,000
Q1 2020 May 15, 2020	SELL	$82.38 - $131.64 $2.41 Million - $3.86 Million	-29,292 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $6.83 Million - $12.1 Million	-89,250 Reduced 75.29%	29,292 $3.78 Million
Q3 2019 Nov 14, 2019	BUY	$72.81 - $156.91 $8.16 Million - $17.6 Million	112,134 Added 1749.91%	118,542 $8.93 Million
Q2 2019 Aug 14, 2019	SELL	$112.21 - $151.95 $969,045 - $1.31 Million	-8,636 Reduced 57.4%	6,408 $974,000
Q1 2019 May 15, 2019	BUY	$106.67 - $151.68 $1.25 Million - $1.78 Million	11,726 Added 353.41%	15,044 $1.79 Million
Q4 2018 Feb 14, 2019	BUY	$97.32 - $148.76 $158,631 - $242,478	1,630 Added 96.56%	3,318 $362,000
Q3 2018 Nov 14, 2018	SELL	$115.31 - $161.51 $704,774 - $987,149	-6,112 Reduced 78.36%	1,688 $273,000
Q2 2018 Aug 14, 2018	BUY	$71.74 - $153.69 $559,572 - $1.2 Million	7,800 New	7,800 $1.03 Million
Q1 2018 May 15, 2018	SELL	$54.02 - $82.27 $52,561 - $80,048	-973 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$47.64 - $56.75 $38,731 - $46,137	-813 Reduced 45.52%	973 $54,000
Q3 2017 Nov 14, 2017	BUY	$35.73 - $47.15 $63,813 - $84,209	1,786	1,786 $81,000

Others Institutions Holding SRPT

# of Institutions

529

Shares Held

84.2M

Call Options Held

2.06M

Put Options Held

1.52M

Black Rock Inc. New York, NY

10.3M
Shares

$1.23 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

8.97M
Shares

$1.07 Billion
0.02% of portfolio
Capital International Investors Los Angeles, CA

6.26M
Shares

$745 Million
0.16% of portfolio
Janus Henderson Group PLC London, X0

4.36M
Shares

$519 Million
0.29% of portfolio
State Street Corp Boston, MA

4.27M
Shares

$508 Million
0.02% of portfolio

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account